Drugs / menaquinone-7
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02870829 | Jul 2016 → Feb 2022 | calcinosis, vitamin K deficiency hemorrhagic disease | National University Health System, Singapore | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05360342 | Mar 2020 → Jul 2021 | vitamin K deficiency hemorrhagic disease | RWTH Aachen University | Completed | No outcome recorded |
| — | NCT00402974 | Jan → Apr 2007 | — | UMC Utrecht | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | menaquinone 7 | “The vitamin K supplement contains 3 subforms of vitamin K: vitamin K1 (1000µg), menaquinone-4 (1000µg) and menaquinone-7 (200µg).” NCT05360342 ↗ |
| Action | Restore | “Vitamin K supplement should therefore correct this anomaly and decrease the rate or severity of vascular calcification in this population of patients on long-term maintenance...” PMID 32899022 ↗ Sep 2020 |
| Route | Oral | “Oral supplement given post dialysis 3x/week” NCT02870829 ↗ |